



Bharat Immunologicals & Biologicals Corporation Limited

BIBCOL

CIN – L24232UP1989GOI010542 (A Govt. of India Undertaking)

Regd. Office: Vill. Chola, Bulandshahr(UP)-Pin 203203

Phone (09458096110), Tele Fax -05732 238757

Email – sklalacs@yahoo.co.in Website- www.bibcol.com

No.BIB/CS/SE/UAFR/2023-24/

Date 31.10.2023

To
The Listing Department
Bombay Stock Exchange
Phiroze jeejeebhoy Tower
25, Dalal Street, Mumbai – 400001

Sub: Submission of Unaudited Quarterly Financial Results alongwith Limited Review Report for the quarter and half year ended September 2023 as Compliance of LODR 2015

Sir/Madam,

In pursuance of the LODR with Stock Exchange, please find enclosed the Unaudited quarterly financial results alongwith Limited Review Report for the quarter and half year ended September 2023 approved by the Board of the Company in its Meeting on 30.10.2023.

This submission of UAFR will succeeded by XBRL filing as per the requirement of Exchange.

Submitted please.

Thanking you,

Sandip Kumar Lal
(G.M.)



Limited Review Report

In case of M/s Bharat Immunologicals and Biologicals Corporation Limited

Review Report to the Shareholders of M/s Bharat Immunologicals and Biologicals Corporation Limited

We have reviewed the accompanying statement of unaudited financial results of **M/s Bharat Immunologicals and Biologicals Corporation Limited** for the period of 1st July, 2023 to 30th September, 2023. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement

Sanjana & Associates
Chartered Accountant
FRN:037966N

Date:-30-10-2023
Place:-Delhi
UDIN:23559855BHBOQV9154



CA Sanjana Garg
M.No.- 559855

BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LIMITED
Registered office at VILLAGE CHOLAPS-KOTALI DEHAT BULANDSAHAR UTTAR PRADESH UP 203203
CIN:- L24232UP1989G01010542

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30-09-2023
Part I
Selected Information for the Period Ended 30-09-2023

| S.No | Particulars | 3 Months Ended on | Preceding 3 Months | Corresponding 3 Months | Half Year Ended on | Previous Year Ended as |
|------|---|---------------------------|------------------------------------|---|---------------------------|----------------------------|
| | | 30-09-2023 (Unaudited) | Ended on 30-06-2023 (Unaudited) | Ended in the previous year 30-09-2022 (Unaudited) | 30-09-2023 (Unaudited) | on 31-03-2023 (Audited) |
| 1 | INCOME | | | | | |
| | a) Income from Operations | - | - | 2,647.96 | - | 4,460.91 |
| | b) Other Income | 16.35 | 10.16 | 31.95 | 26.51 | 106.03 |
| | Total Revenue (1) | 16.35 | 10.16 | 2,679.91 | 26.51 | 4,566.94 |
| 2 | EXPENDITURE | | | | | |
| | a) Cost of Material Consumed | - | -0.26 | 10.61 | -0.26 | 3,304.37 |
| | b) Purchase of Stock in Trade | - | - | - | - | - |
| | c) Change in Inventory of Finished Goods, Work in Progress and Stock in Trade | - | - | - | - | - |
| | d) Employees Benefits | 397.70 | 389.99 | 2,427.29 | 787.69 | 595.20 |
| | e) Finance Cost | 208.73 | 172.12 | 394.98 | 87.69 | 1,514.46 |
| | f) Depreciations and Amortisation Expense | 3.43 | 3.43 | 174.22 | 380.85 | 704.86 |
| | g) Other Expense | 71.13 | 41.65 | 3.65 | 6.86 | 19.98 |
| | Total Expense (2) | 680.99 | 606.93 | 3,075.83 | 1,287.92 | 6,793.73 |
| 3 | Profit/ (Loss) before exceptional items (1-2) | -664.64 | -596.77 | -395.92 | -1,261.41 | -2,226.79 |
| 4 | Tax Expense | - | - | - | - | - |
| | a) Current Tax | - | - | - | - | - |
| | b) Deferred Tax | -172.81 | -138.04 | -87.60 | -310.85 | -562.91 |
| 5 | Profit/ (Loss) from continuing Operations (3-4) | -491.83 | -458.73 | -308.31 | -950.56 | -1,663.88 |
| 6 | Other Comprehensive Income/(Loss) (Net of Taxes) | - | - | - | - | - |
| 7 | Total Comprehensive Income/(Loss) for the period (5+6) | -491.83 | -458.73 | -308.31 | -950.56 | -1,663.88 |
| 8 | Paid Up Equity Share Capital (Face Value of INR 10/- each) | 4,318.00 | 4,318.00 | 4,318.00 | 4,318.00 | 4,318.00 |
| 9 | Earning Per Share (of INR 10/- each) not annualised | | | | | |
| | a) Basic | -1.14 | -1.06 | -0.71 | -2.20 | -3.85 |
| | b) Diluted | -1.14 | -1.06 | -0.71 | -2.20 | -3.85 |

Note - Refer our Note Separately

(INR in Lakh)

Srip.

BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LIMITED
Registered office at VILLAGE CHOLAPS-KOTALI DEHAT BULANDSAHAR UTTAR PRADESH UP 203203
CIN:- L24232UP1989G010542

Part II
Selected Information for the Period Ended 30-09-2023

| S.No | Particulars | 3 Months Ended on 30-09-2023 (Unaudited) | Preceding 3 Months Ended on 30-06-2023 (Unaudited) | Corresponding 3 Months Ended in the previous year 30-09-2022 (Unaudited) | Half Year Ended on 30-09-2023 (Unaudited) | Previous Year Ended as on 31-03-2023 (Audited) |
|----------|---|---|---|---|--|---|
| A1 | PARTICULARS OF SHAREHOLDING | | | | | |
| | Public shareholding | | | | | |
| | - Number of Shares | 1,75,94,000.00 | 1,75,94,000.00 | 1,75,94,000.00 | 1,75,94,000.00 | 1,75,94,000.00 |
| | - Percentage of shareholding | 40.75 | 40.75 | 40.75 | 40.75 | 40.75 |
| A2 | Promoters and Promoters Group shareholding | | | | | |
| | a) Pledged/ Encumbered | | | | | |
| | - Number of Shares | - | - | - | - | - |
| | - Percentage of shareholding (as a% of the total shareholding of promoter and promoter group) | - | - | - | - | - |
| | - Percentage of shareholding (as a% of the total share capital of the company) | - | - | - | - | - |
| | b) Non - encumbered | | | | | |
| | - Number of Shares | 2,55,86,000.00 | 2,55,86,000.00 | 2,55,86,000.00 | 2,55,86,000.00 | 2,55,86,000.00 |
| | - Percentage of shareholding (as a% of the total shareholding of promoter and promoter group) | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 |
| | - Percentage of shareholding (as a% of the total share capital of the company) | 59.25 | 59.25 | 59.25 | 59.25 | 59.25 |
| B | Particulars | 3 Months ended (30-09-2023) | | | | |
| | INVESTOR COMPLAINTS | | | | | |
| | Pending at the beginning of the quarter | - | - | - | - | - |
| | Received during the quarter | - | - | - | - | - |
| | Disposed of during the quarter | - | - | - | - | - |
| | Remaining unresolved at the end of the quarter | - | - | - | - | - |

SLP.

BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LIMITED
Registered office at VILLAGE CHOLAPS-KOTOALI DEHAT BULANDSAHAR UTTAR PRADESH UP 203203
CIN:- L24232UP1989GO1010542

Segment Reporting for the Period Ended 30-09-2023

(INR in Lakhs)

| S.No | Particulars | 3 Months Ended on 30-09-2023 | Preceding 3 Months Ended on 30-06-2023 | Corresponding 3 Months Ended in the previous year 30-09-2022 | Half Year Ended on 30-09-2023 | Previous Year Ended as on 31-03-2023 |
|------|---|---------------------------------|---|--|----------------------------------|---|
| 1 | SEGMENT REVENUE | | | | | |
| | Oral Polio Vaccine | - | - | 2,647.96 | - | 4,460.88 |
| | Zinc Dispersible Tablets | - | - | - | - | - |
| | BIB Sweet Tablets | - | - | - | - | 0.03 |
| | BIBSANTI | - | - | - | - | - |
| | Less: Intersegment revenue | - | - | - | - | - |
| | Net Sales/ Income from operations | - | - | 2,647.96 | - | 4,460.91 |
| 2 | SEGMENT RESULTS (Profit Before Tax) | | | | | |
| | Oral Polio Vaccine | -491.83 | - | -308.31 | -491.83 | -1,663.88 |
| | Zinc Dispersible Tablets | - | - | - | - | - |
| | BIB Sweet Tablets | - | - | - | - | - |
| | BIBSANTI | - | - | - | - | - |
| | Less: Unallocable expenditure net off unallocable Income | - | - | - | - | - |
| | Total Profit before Tax | -491.83 | - | -308.31 | -491.83 | -1,663.88 |
| 3 | CAPITAL EMPLOYED (Segment Assets less Liabilities) | | | | | |
| | Oral Polio Vaccine | 18,117.85 | 18,311.17 | 19,144.51 | 18,117.85 | 18,184.19 |
| | Zinc Dispersible Tablets | -226.10 | -226.10 | -226.10 | -226.10 | -226.10 |
| | BIB Sweet Tablets | - | - | - | - | - |
| | BIBSANTI | - | - | - | - | - |
| | Others* | 921.38 | 901.52 | 1,109.86 | 921.38 | 906.64 |
| | Total Capital employed | 18,813.13 | 18,986.59 | 20,028.27 | 18,813.13 | 18,864.73 |

Note: * Represents OCV, DNK, Upgradation of OPV & BOPV Projects

S.P.

Bharat Immunologicals and Biologicals Corporation Limited
Statement of Assets & Liabilities as on 30th September 2023

| Particulars | | Note No. | As at 30th September 2023 | As at 31st March 2023 |
|-------------|---|----------|---------------------------------|--------------------------|
| A | ASSETS | | | |
| 1 | Non-current assets | | | |
| | (a) Property, Plant and Equipment | 4 | 11,521.52 | 11,574.65 |
| | (c) Financial Assets | 5 | 928.18 | 928.18 |
| | (d) Other non-current assets | 6 | 44.84 | 44.84 |
| | (e) Non Current Tax Assets (Net) | 7 | 71.22 | 71.20 |
| | (f) Deferred tax assets (net) | 8 | 2,976.37 | 2,665.54 |
| | | | 15,542.14 | 15,284.41 |
| 2 | Current assets | | | |
| | (a) Inventories | 9 | 142.40 | 142.21 |
| | (b) Financial Assets | | | |
| | (i) Investments | | | |
| | (ii) Trade receivables | 10 | 1,002.56 | 1,387.59 |
| | (ii) Cash and cash equivalents | 11 | 145.83 | 128.59 |
| | (iii) Bank balances other than (ii) above | 12 | 745.10 | 745.10 |
| | (c) Other current assets | 13 | 1,235.10 | 1,176.78 |
| | | | 3,271.00 | 3,580.28 |
| | Total | | 18,813.13 | 18,864.73 |
| B | EQUITY AND LIABILITIES | | | |
| 1 | Equity | | | |
| | (a) Equity Share capital | 14 | 4,318.00 | 4,318.00 |
| | (b) Other Equity | 15 | 3,552.87 | 4,503.43 |
| | | | 7,870.87 | 8,821.43 |
| 2 | Non-current liabilities | | | |
| | (a) Deferred Grant | 16 | 0 | - |
| | (b) Long Term Provisions | 17 | 691.00 | 639.06 |
| | (c) Long Term Loans | 18 | 350.00 | |
| | | | 1,041.00 | 639.06 |
| 3 | Current liabilities | | | |
| | (a) Financial Liabilities | | | |
| | (i) Borrowings | 19 | 7,086.44 | 7,022.49 |
| | (ii) Trade payables | 20 | 77.85 | 103.14 |
| | (iii) Other Financial Liabilities | 21 | 99.20 | 124.72 |
| | (b) Short Term Provisions | 23 | 728.00 | 685.55 |
| | (c) Other Current liabilities | 24 | 1,913.98 | 1,468.34 |
| | | | 9,905.48 | 9,404.24 |
| | Total | | 18,813.13 | 18,864.73 |

C. S. P.